GGrantIndex
Sort

141,003 grants matching cytokine

A Phase II Evaluation of the Safety and Protective Efficacy of the Live Attenuated Tetravalent Dengue Vaccine TetraVax-DV with Challenge by the Recombinant DENV-2 Virus in a Dengue Endemic Population

$1,249,406
Beth Diane Kirkpatrick · University Of Vermont & St Agric College · U01 · FY2023 · AI

Transplant Arteriosclerosis: Viral and Host Mechanism

$1,249,305
Stanford University · P01 · FY2001 · AI

Cellular and Developmental Biology of Coxiella burnetii

$1,249,247
Robert A Heinzen · Niaid Extramural Activities · Z01 · FY2007 · AI

RAGE and Mechanisms of Vascular Dysfunction

$1,249,231
Columbia University Health Sciences · P01 · FY2004 · HL

Signaling in Airway Inflammation

$1,249,085
Allan R. Brasier · University Of Texas Med Br Galveston · P01 · FY2007 · AI

Multiscale Analysis of Immune Responses

$1,248,975
Ronald Germain · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Epigenetic Regulation of T cell differentiation

$1,248,881
Keji Zhao · National Heart, Lung, And Blood Institute · ZIA · FY2024 · HL

Development of a novel anti-neuroinflammatory experimental therapeutic for epilepsy and Alzheimer's risk

$1,248,699
Victor Shifrin · Immunochem Therapeutics, Llc · R44 · FY2024 · AG

HIV-1 SHEDDING FROM FEMALE GENITAL TRACT

$1,248,693
University Of Washington · P01 · FY2004 · HD

Restoration of free radical homeostasis: novel therapy of septic shock

$1,248,631
Andrew L Salzman · Radikal Therapeutics, Inc. · R44 · FY2016 · GM

Development of a novel adjuvant for vaccine sparing

$1,248,398
Sara Lustigman · New York Blood Center · R01 · FY2017 · AI

Tumor Intrinsic and Microenvironmental Mechanisms Driving Drug Combination Efficacy and Resistance in AML

$1,248,330
Jeffrey Wallace Tyner · Oregon Health & Science University · U54 · FY2019 · CA

Investigating mammalian innate immune responses to pathogenic fungi

$1,248,202
Eric Dang · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI

Animal models of eye diseases

$1,248,149
Sheldon Miller · National Eye Institute · ZIA · FY2013 · EY

Development of an Innovative Material for Transcatheter Peripheral Embolization

$1,247,814
Ehsan Jabbarzadeh · Obsidio, Inc. · R44 · FY2022 · HL

Allergen-induced extracellular DNA in type 2 immunity

$1,247,804
Hirohito Kita · Mayo Clinic Arizona · R01 · FY2025 · AI

Innate inflammatory responses during pulmonary infections

$1,247,742
Katrin Mayer-Barber · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI

SCOR IN ACUTE LUNG INJURY

$1,247,617
University Of Iowa · P50 · FY2002 · HL

ACUTE INFECTION AND EARLY DISEASE RESEARCH NETWORK

$1,247,493
Johns Hopkins University · U01 · FY2001 · AI

Epigenetic Therapy for Thoracic Malignancies

$1,247,492
David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2024 · CA

Disappearing gastrointestinal microbiota in epidemic obesity.

$1,247,198
Martin J Blaser · New York University School Of Medicine · R01 · FY2012 · DK

GrowthDifferentiation Factors in Organogenesis

$1,246,888
Alan Perantoni · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA

Chinese Herbal Medicine as a Novel Paradigm for Cancer Chemotherapy

$1,246,839
Yung-Chi Cheng · Yale University · P01 · FY2014 · CA

Uterine Leiomyoma Research Center Program

$1,246,816
Serdar E Bulun · Northwestern University At Chicago · P01 · FY2015 · HD

Mapping the perivascular reticular network in health, aging, and AD

$1,246,362
Rupal I. Mehta · Rush University Medical Center · RF1 · FY2023 · AG